An observational study in Carotid Stenosis and Ocular Blood Flow, sponsored by University of Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 150 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by University of Bologna · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Carotid Stenosis with a site in Italy — 3 open to participants now, 5 under way, none of them phase 3. Carotid Stenosis · Italy.
Among the 22 studies in Carotid Stenosis with a site in Italy, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2027, is one of 11 observational ones, and was the 22nd registered.
369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.
Browse Carotid Stenosis studies →3 of the 22 studies in Carotid Stenosis with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 150 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 176 across 161 observational studies indexed under Carotid Stenosis.
Median enrollment 150 across the 11 interventional studies, 200 across the 11 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
University of Bologna is the lead sponsor of 160 studies on the registry; 26 are open to participants now.
University of Bologna has 2 studies filed under Carotid Stenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Carotid Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The management of atherosclerotic carotid disease, according to current guidelines, is primarily based on the quantification of the degree of carotid stenosis, together with the assessment of its hemodynamic significance and the presence of neurological symptoms, such as transient ischemic attack (TIA) or stroke. However, these parameters may not fully reflect the hemodynamic impact of carotid lesions on peripheral vascular territories, particularly the ocular circulation.
The eye represents the only vascular territory that can be directly visualized in vivo, providing a unique "window" into the microcirculation. Retinal and choroidal abnormalities resulting from chronic hypoperfusion may reflect the degree of hemodynamic impairment associated with carotid disease and provide additional information beyond the anatomical characteristics of the stenosis identified by vascular imaging alone.
From a vascular surgery perspective, ophthalmological assessment and fundus examination could allow a more accurate phenotypic characterization of patients with carotid disease, identifying individuals in whom carotid stenosis has already resulted in end-organ microvascular consequences despite the absence of major neurological manifestations. In the era of personalized medicine, such a multidisciplinary approach could move beyond a purely morphological assessment of carotid plaque by incorporating functional and clinical parameters that may potentially contribute to therapeutic decision-making.
The results of the present study may therefore help define the role of fundus examination, combined with a more comprehensive assessment of ocular symptoms, as a complementary tool in the evaluation of patients with carotid stenosis. This approach may facilitate a more accurate identification of patients at higher risk of disease progression and cerebrovascular ischemic events, while potentially improving the selection of candidates for carotid revascularization procedures
Patients with asymptomatic carotid artery stenosis and ocular alterations
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with asymptomatic carotid artery stenosis and ocular symptoms
Correlation between carotid stenosis and ocular symptoms
Any ocular alteration correlated to carotid stenosis
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2037, 126 months later.
Of 79 non-industry observational studies under Carotid Stenosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 104. This study's planned 126 months is above that.
Counting every sponsor, half of 87 studies reached it within 50 months; a quarter within 30 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.